Product Description
Mechanisms of Action: CYP3A4 Inhibitor, TK Inhibitor, EGFR Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Astellas Pharma
Company Location:
Company Founding Year: 2005
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 3: Non-Small-Cell Lung Cancer
Phase 2: Non-Small-Cell Lung Cancer|Small Cell Lung Cancer
Phase 1: Oncology Solid Tumor Unspecified|Non-Small-Cell Lung Cancer
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT02113813 |
8273-CL-0102 | P1 |
Completed |
Non-Small-Cell Lung Cancer |
2017-07-28 |
12% |
2019-08-10 |
Primary Endpoints|Start Date|Treatments |
NCT03082300 |
8273-CL-0112 | P1 |
Terminated |
Non-Small-Cell Lung Cancer |
2017-05-12 |
2019-03-21 |
Treatments |
|
NCT02674555 |
8273-CL-0104 | P1 |
Withdrawn |
Oncology Solid Tumor Unspecified |
2016-11-15 |
2019-03-20 |
Treatments |
|
NCT02500927 |
8273-CL-0202 | P2 |
Terminated |
Non-Small-Cell Lung Cancer|Small Cell Lung Cancer |
2017-06-09 |
2019-03-20 |
Treatments |
|
NCT03042013 |
8273-CL-0201 | P2 |
Withdrawn |
Small Cell Lung Cancer|Non-Small-Cell Lung Cancer |
2017-02-28 |
2019-03-21 |
Treatments |
|
NCT02192697 |
8273-CL-0101 | P2 |
Terminated |
Non-Small-Cell Lung Cancer |
2016-01-15 |
2019-10-18 |
Primary Endpoints|Study Completion Date|Treatments |
|
NCT02588261 |
SOLAR | P3 |
Terminated |
Non-Small-Cell Lung Cancer |
2017-12-21 |
22% |
2019-03-20 |
|
2015-002894-39 |
SOLAR | P3 |
Completed |
Non-Small-Cell Lung Cancer |
2017-12-21 |
22% |
2025-06-28 |
Treatments |